Poxel
France - LyonBiotechnology
Focus: Poxel is a French biotechnology company founded in 2021 focused on developing drugs for metabolic diseases. The company is based in Lyon and operates in the pre-revenue biotech space.
Profile data last refreshed 2d ago · AI intelligence enriched 2w ago
Open Jobs
0
About Poxel
AI assessmentNot HiringNo open roles listed right now. Follow Poxel to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
14 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Imeglimin Reference product
BioequivalenceClinical Trials (1)
NCT03646331Bioequivalence of Imeglimin Tablet Formulations
Phase 1Help build intelligence for Poxel
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.